Craig Fox

Craig joined Oxford Science Enterprises as Operating Partner in the Life Sciences team in February 2022. He supports the growth and development of Oxford Science Enterprises’ Life Science businesses, the identification of new opportunities, and formation of new spinouts.

Craig is an experienced biologist and NIH funded Principal Investigator who has managed and worked on numerous drug discovery and development projects over more than 20 years in the industry, from initial target selection right through to investigating clinical efficacy and safety in Phase 2 patient studies.

Prior to joining C4XD, he was Director of Respiratory Research at Pulmagen Therapeutics where he managed several of its programmes, collaborations and partnerships, including those with AstraZeneca, Teijin Pharma and Chiesi. Craig has also previously worked for Argenta Discovery, Etiologics Ltd and Bayer plc and has a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.

Craig is an experienced biologist and NIH funded Principal Investigator who has managed and worked on numerous drug discovery and development projects over more than 20 years in the industry, from initial target selection right through to investigating clinical efficacy and safety in Phase 2 patient studies.

Prior to joining Oxford Sciences he was Chief Scientific Officer and an Executive Board Member at C4X Discovery for more than six years, guiding its transition from a technology-based company to a therapeutics business, raised >£35m on the UK public market, forged strategic collaborations and oversaw an emerging drug discovery pipeline that has led to multiple licensing deals with Pharma. Prior to joining C4XD, he was Director of Respiratory Research at Pulmagen Therapeutics where he managed several of its programmes, collaborations and partnerships, including those with AstraZeneca, Teijin Pharma and Chiesi. Craig has a PhD in Respiratory Medicine and has also previously worked for Argenta Discovery, Etiologics Ltd and Bayer plc.

Craig has a PhD in Respiratory Medicine from Birmingham University and a first-class Biochemistry degree from the University of Surrey.